Severity of overactive bladder symptoms and response to dose escalation in a randomized, double‐blind trial of solifenacin ( <scp>SUNRISE</scp> )

Abstract

Increasing the solifenacin dose to 10 mg further improved OAB symptoms in patients who requested a dose increase after 8 weeks' treatment with 5 mg solifenacin. The present study supports the view that patients with severe OAB symptoms benefit from a higher antimuscarinic dose.